Company
Apellis Pharmaceuticals, Inc. (APLS)
Standardized SEC financial data for Apellis Pharmaceuticals, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001492422 · NASDAQ · Pharmaceutical Preparations.
Operating margin
5.5%
Net margin
2.2%
Revenue growth (YoY)
28.5%
Return on equity
6.0%
Free cash flow
$45.0M
Debt / equity
0.25×
Current ratio
3.14×
EPS (diluted)
$0.20
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $250.6M | $66.6M | $75.4M | $396.6M | $781.4M | $1.00B |
| R&D expense |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $567.0M | $641.8M | $553.1M | $352.3M | $412.6M | $467.8M |
| Inventory |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$160.5M | -$563.1M | -$513.7M | -$594.7M | -$87.9M | $45.3M |
| Capital expenditures |
Get APLS data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/APLS/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/APLS/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"